Kamada (XTAE:KMDA) Change In Working Capital : ₪-67.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Kamada Change In Working Capital?

Kamada's change in working capital for the quarter that ended in Mar. 2024 was ₪-24.3 Mil.

Kamada's change in working capital for the fiscal year that ended in Dec. 2023 was ₪-66.8 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Kamada Change In Working Capital Historical Data

The historical data trend for Kamada's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Change In Working Capital Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-6.30

-26.07

-52.90

42.76

-66.82

Kamada Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-23.18	-13.59	-23.62	-6.43	-24.31

Kamada Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-67.9 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Kamada Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Kamada's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (XTAE:KMDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

KMDA:USA

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.